GeoVax’s Dr. Harriet Robinson – a key conference speaker on “the State of the Art Session” VGXI Inc.’s Robert J. Juba – speaker on Manufacturing a High Concentration Multi-Component DNA Vaccine Las Vegas, NV – December 8, 2008 GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta-based biopharmaceutical company developing human vaccines for diseases caused by… Read More »
GeoVax Labs and VGX International Announce Agreement at the Las Vegas “International Society of DNA Vaccines” Conference
VGX International signs a Master Product Sale Agreement with BioCancell Therapeutics of Israel to supply plasmid for its multiple clinical programs
VGXI, Inc. today announced the execution of a Master Product Sale Agreement to supply plasmid between its parent company, VGX International, and BioCancell Therapeutics. BioCancell is a biopharmaceuticals corporation specializing in the development of Patient-Oriented, Targeted Therapy for the treatment of numerous types of cancer. Products under the Agreement will be manufactured at the VGXI,… Read More »
Senesco Chooses VGXI To Produce Factor 5A Plasmid
Senesco Technologies, Inc. ("Senesco" or the "Company") (AMEX:SNT) announced today that it has contracted with VGXI, Inc. (The Woodlands, TX) (“VGXI”) to supply the plasmid portion of the Company’s combination therapy consisting of the Factor 5A gene and siRNA against Factor 5A. Senesco has previously reported positive preclinical in vivo results using its combination siRNA… Read More »
VGX Pharmaceuticals announces filings of two separate INDs covering novel DNA vaccines: one for cervical cancer therapy (VGX-3100) and one for avian influenza (VGX-3400)
VGX Pharmaceuticals announced today that it has submitted two separate investigational new drug (IND) applications to the U.S. Food and Drug Administration (FDA) for Phase I clinical studies of VGX-3100 and VGX-3400. Both candidate vaccines are based on VGX’s SynCon™ vaccine technology, and they have been developed using VGX’s integrated DNA Vaccines and Therapies Platform…. Read More »
VGX Pharmaceuticals signs multi-year production agreement with the United Kingdom Cystic Fibrosis Gene Therapy Consortium
VGX Pharmaceuticals (VGX) today announced that the Company has signed a multi-year supply agreement to provide plasmid DNA to support the ongoing toxicology and clinical trials of the United Kingdom Cystic Fibrosis Gene Therapy Consortium comprising over 80 scientists and clinicians in Edinburgh, London and Oxford dedicated to the search for effective gene therapy to… Read More »
VGX Pharmaceuticals announces the IND filing of VGX-3200, a novel DNA therapy that utilizes GHRH for the treatment of cancer cachexia and anemia
VGX Pharmaceuticals today announced it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for Phase I clinical studies of VGX-3200 in late stage cancer patients. VGX-3200 is an injectable DNA plasmid-based therapeutic that expresses human Growth Hormone Releasing Hormone (GHRH) protein. VGX’s innovative DNA delivery technology allows… Read More »
VGX Pharmaceuticals Announces Initiation of VGX-cGMP Manufactured Plasmid Products in Clinical Use by Partners
VGX Pharmaceuticals today announced that the DNA plasmid-based product manufactured by VGX on behalf of Nucleonics,Inc. has entered Phase I human clinical trials in the United States and Europe for the treatment of chronic Hepatitis B virus (HBV) infection. The Nucleonics’ HBV clinical candidate (NUC B1000) is an expressed interfering RNA (eiRNA) based product, consisting… Read More »
VGX Animal Health announces approval of LifeTide™ SW 5 – World’s First and Only Approved DNA Therapy for Food Animals
VGX Animal Health, Inc. (VGXAH), a developer of cutting edge technologies for animal health applications, announced today the approval by the Australian Pesticides and Veterinary Medicines Authority (APVMA) of LifeTide™ SW 5, the Company’s leading Growth Hormone Releasing Hormone (GHRH) product for swine therapy. LifeTide™ SW 5 is an injectable DNA plasmid encoding for porcine… Read More »